Candesartan (Synonyms: Candesartan M1, CV-11974) |
| رقم الكتالوجGC16978 |
كانديسارتان (CV 11974) هو مانع لمستقبلات الأنجيوتنسين II AT1 و PPAR-النشط عن طريق الفم
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 139481-59-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Candesartan is an oral blocker of AngII type-1 receptors (AT1R), with an IC50 value of 0.26nM[1]. Candesartan can inhibit the viral activity of SARS-CoV-2 with an IC50 value of 5.944μM[2]. Candesartan has been widely used to inhibit renal vasoconstriction in rodents, blocking AT1A and AT1B receptors in rodent renal resistance vessels[3].
In vitro, Candesartan treatment at 20µM for 24h significantly induced apoptosis and inhibited cell migration in CT-26 and SW-480 cells [4]. Treatment of human embryonic kidney epithelial cells with 100μM Candesartan for 24h significantly reduced TNF-α-induced TGF-β and IL-6 expression and blocked TNF-α-induced ROS activation[5]. Treatment with 1μM Candesartan for 48h specifically reversed the AngII-induced decrease in miR-301b levels in rat aortic smooth muscle cells (RASMCs) and significantly reduced the AngII-induced increase in STAT3 expression[6].
In vivo, Candesartan treatment via oral administration at a dose of 2mg/kg/day for 28 days significantly reduced tumor volume and inhibited tumor angiogenesis in the murine xenograft model of bladder cancer[7]. Intraperitoneal administration of Candesartan (10mg/kg/day) for 7 days significantly reduced pathological neovascularization and improved capillary perfusion in a mouse model of ischemic retinopathy[8]. Oral administration of Candesartan at a dose of 1mg/kg/day for 21 days significantly improved insulin resistance, hepatic steatosis, and dyslipidemia in the high-fat diet (HFD)-fed mice[9].
References:
[1] Abreu Diaz A M, Drumeva G O, Petrenyov D R, et al. Synthesis of the novel AT1 receptor tracer [18F] fluoropyridine–candesartan via click chemistry[J]. Acs Omega, 2020, 5(32): 20353-20362.
[2] Alnajjar R, Mostafa A, Kandeil A, et al. Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease[J]. Heliyon, 2020, 6(12).
[3] Ruan X, Purdy K E, Oliverio M I, et al. Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice[J]. Journal of the American Society of Nephrology: JASN, 1999, 10: S202-7.
[4] Tabatabai E, Khazaei M, Asgharzadeh F, et al. Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer[J]. Excli Journal, 2021, 20: 863.
[5] Yu Y, Jiang H, Niu Y, et al. Candesartan inhibits inflammation through an angiotensin II type 1 receptor independent way in human embryonic kidney epithelial cells[J]. Anais da Academia Brasileira de Ciências, 2019, 91(02): e20180699.
[6] Zhang L, Yang F, Yan Q. Candesartan ameliorates vascular smooth muscle cell proliferation via regulating miR-301b/STAT3 axis[J]. Human Cell, 2020, 33(3): 528-536.
[7] Kosugi M, Miyajima A, Kikuchi E, et al. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer[J]. Clinical cancer research, 2006, 12(9): 2888-2893.
[8] Shanab A Y, Elshaer S L, El-Azab M F, et al. Candesartan stimulates reparative angiogenesis in ischemic retinopathy model: role of hemeoxygenase-1 (HO-1)[J]. Angiogenesis, 2015, 18(2): 137-150.
[9] Lee J W, Gu H O, Jung Y, et al. Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation[J]. Experimental & molecular medicine, 2023, 55(5): 910-925.
| Cell experiment [1]: | |
Cell lines | CT-26 cells |
Preparation Method | CT-26 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37.0°C and 5% CO2 humidity. CT-26 cells (1×103) were seeded in 96-well plates and treated with various concentrations of Candesartan (100, 200, 400, 600, 800, and 1000μM) for 24 hours. After cell treatment, 20μl of MTT solution (5mg/ml) was transferred to each well, and the culture plates were incubated at 37°C for 4h to investigate the production of formazan crystals by living cells. Subsequently, the medium was replaced with DMSO (100μl), and the optical density was then measured at 545-630nm. |
Reaction Conditions | 100, 200, 400, 600, 800, and 1000μM; 24h |
Applications | Candesartan significantly inhibited the viability of CT-26 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Nude athymic BALB/c mice |
Preparation Method | Nude athymic BALB/c mice of 6 weeks of age with an average weight of 20g were maintained under standard conditions. KU-19-19 cells (2×106 cells) suspended in 50μl Matrigel were subcutaneously implanted into the flank of each nude mouse. The mice were divided into 2 groups, with about 20 mice in each group. Starting on the day of cell implantation, mice were injected with 2mg/kg Candesartan daily via gavage, and tumors were measured twice weekly. The tumor volume (V) was calculated according to the formula V = AB2/2, where A is the maximum diameter and B is the diameter perpendicular to A. Mice were sacrificed on day 28, and subcutaneous tumors were harvested for analysis. |
Dosage form | 2mg/kg/day for 28 days; p.o. |
Applications | Candesartan treatment significantly reduced tumor volume and inhibited tumor angiogenesis in mice. |
References: | |
| Cas No. | 139481-59-7 | SDF | |
| المرادفات | Candesartan M1, CV-11974 | ||
| Chemical Name | 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid | ||
| Canonical SMILES | CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O | ||
| Formula | C24H20N6O3 | M.Wt | 440.45 |
| الذوبان | ≥ 14.65mg/mL in DMSO, ≥ 3.45 mg/mL in EtOH with ultrasonic | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2704 mL | 11.352 mL | 22.7041 mL |
| 5 mM | 454.1 μL | 2.2704 mL | 4.5408 mL |
| 10 mM | 227 μL | 1.1352 mL | 2.2704 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *